Skip to main content

Table 4 Survival parameters - CR versus non CR after ASCT. Patients 61–65 years. Number of patients evaluable for treatment response = 72

From: Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

  Median Overall Survival (Months) (95%CI) Median Time to New Treatment (Months) (95%CI)
CR1 Non CR2 P- value CR Non CR P-value
Period 13 (N = 32) 59.8 (41.0–78.5) 52.1 (8.4–95.8) P = 0.8 (ns) 28.7 (5.0.-51.4) 35.7 (14.9–56.5) P = 0.8 (ns)
Period 24 (N = 40) 75.0 (46.3–102.6) 50.1 (42.1–68.1) P = 0.2 (ns) 56.4 (32.4–80.9) 29.9 (16.4–39.3) P = 0.02
Period 1 + 2 (N = 72) 68.5 (51.7–85.4) 52.3 (48.1–56.1) P = 0.4 43.9 (28.7–59.0) 31.3 (24.3–37.8) P = 0.04
  1. 1Number of CR patients: Period 1: 6/32 Period 2: 13/40 Total 19
  2. 2Number of non CR patients Period 1: 26/32 Period 2: 27/40 Total 53
  3. 3Period 1 = 01.01.2001–31.06.2005
  4. 4Period 2 = 01.07.2005–31.12.2009